An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome

Pediatric Infectious Disease Journal

Volumn 28, Issue 4, 2009, Pages 339-341

  Eguchi, Taisuke ^a   Nomura, Yuichi ^a   Hashiguchi, Teruto ^a   Masuda, Kiminori ^b   Arata, Michiko ^a   Hazeki, Daisuke ^a   Ueno, Kentaro ^a   Nishi, Junichiro ^a   Kawano, Yoshifumi ^a   Maruyama, Ikuro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kagoshima City Hospital   (Japan)

Author keywords

High mobility group box 1; Immunoglobulin treatment; Kawasaki syndrome; Treatment failure

Indexed keywords

ACETYLSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; BIOLOGICAL MARKER;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; INFANT; NONPARAMETRIC TEST; PRESCHOOL CHILD; ROC CURVE;

BIOLOGICAL MARKERS; CHILD, PRESCHOOL; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LEUKOCYTE COUNT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 65649093347     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818ffe60     Document Type: Article

References (10)

1. Roweley AH, Shulman ST. Kawasaki disease. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Textbook of Pediatrics. 18th ed. Philadelphia, PA: WB Saunders; 2007:1036 -1042.
2. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114:1708 -1733.
3. Goodwin GH, Sanders G, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973;38:14 -19.
4. Wan H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001;164:1768 -1773.
5. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565-570.
6. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232-234.
7. Kurotobi S, Nagai T, Kawakami N, et al. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int. 2002;44: 1-4.
8. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606 -2612.
9. Enrione MA, Powell KR. Sepsis, septic shock, and systemic inflammatory response syndrome. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Textbook of Pediatrics. 18th ed. Philadelphia, PA: WB Saunders; 2007: 1094-1099.
10. Yonggang Sha, Jaroslaw Zmijewski, Zhiwei Xu, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol.2008,180:2531-2537.